Literature DB >> 16596804

Soy, isoflavones and atherosclerosis.

R St Clair1, M Anthony.   

Abstract

Consumption of soy protein is associated with a lower risk of cardiovascular disease in man, and reduced atherosclerosis in a variety of experimental animals. Although a portion of the cardiovascular protective effects appears to be due to reductions in plasma lipoprotein concentration, in most people the magnitude of this effect is relatively small. In many, but not all studies using animal models, the reduction in atherosclerosis is in part independent of changes in plasma lipids and lipoproteins. This implies that there may be a direct effect on the arterial wall of one or more of the components in soyprotein that reduces susceptibility to atherosclerosis. The most actively studied components of soy protein that may be responsible for these anti-atherogenic effects are the isoflavones and various protein factions. Extraction of isoflavones and other alcohol-soluble components from soy protein lowers, but does not eliminate its ability to reduce atherosclerosis. Surprisingly, in most studies, adding back the isoflavone-rich alcohol extract to the previously extracted soy protein, or to another protein, does not restore its lipoprotein lowering or anti-atherogenic properties. This implies that alcohol extraction either destroys an active component of soy, alters the structural integrity of the soy proteins, or disassociates a required isoflavone-soy protein complex. Understanding the mechanism of this effect is an important goal for future research. Likewise, the sites of action on the arterial wall, and the mechanisms by which various soy components act to reduce atherosclerosis are just now being studied. The recent demonstration that expression of estrogen receptor alpha is required for atheroprotection by soy protein provides important new mechanistic insight. Other properties of soy, including antioxidant, anti-inflammatory and potentially antithrombogenic properties need to be explored more mechanistically before the full potential of dietary soy protein for the protection from cardiovascular disease will be known.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596804     DOI: 10.1007/3-540-27661-0_10

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  5 in total

1.  Soy protein containing isoflavones favorably influences macrophage lipoprotein metabolism but not the development of atherosclerosis in CETP transgenic mice.

Authors:  Leiko Asakura; Patrícia M Cazita; Lila M Harada; Valéria S Nunes; Jairo A Berti; Alessandro G Salerno; Daniel F J Ketelhuth; Magnus Gidlund; Helena C F Oliveira; Eder C R Quintão
Journal:  Lipids       Date:  2006-07       Impact factor: 1.880

2.  Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity.

Authors:  A Crespillo; M Alonso; M Vida; F J Pavón; A Serrano; P Rivera; Y Romero-Zerbo; P Fernández-Llebrez; A Martínez; V Pérez-Valero; F J Bermúdez-Silva; J Suárez; F R de Fonseca
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

3.  Replacement of dietary soy protein isolate with concentrates of soy 7S or 11S globulin has minimal or no effects on plasma lipoprotein profiles and biomarkers of coronary risk in monkeys.

Authors:  Michael R Adams; Mary S Anthony; Haiying Chen; Thomas B Clarkson
Journal:  Atherosclerosis       Date:  2007-03-09       Impact factor: 5.162

4.  Current knowledge and future direction of research on soy isoflavones as a therapeutic agents.

Authors:  V Kalaiselvan; M Kalaivani; A Vijayakumar; K Sureshkumar; K Venkateskumar
Journal:  Pharmacogn Rev       Date:  2010-07

5.  Analysis of Flavonoid Metabolites in Chaenomeles Petals Using UPLC-ESI-MS/MS.

Authors:  Ting Shen; Fengting Hu; Qianrui Liu; Haiyan Wang; Houhua Li
Journal:  Molecules       Date:  2020-09-02       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.